Guardant Health
Guardant Health Begins Study of Reveal Liquid Biopsy Test to Predict Cancer Recurrence
The company hopes the study will allow it to expand the use of its ctDNA test to monitor disease recurrence in patients with tumors other than colorectal cancer.
ESMO Data in HER2-Positive Lung, Breast Cancer Bolster Daiichi Sankyo, AstraZeneca's Enhertu
Premium
Studies showed that the antibody-drug conjugate benefited HER2-mutated NSCLC patients and outperformed Genentech's T-DM1 in HER2-positive, previously treated breast cancer.
MD Anderson Study Further Supports Using Liquid Biopsy First to Gauge EGFR Mutations in Lung Cancer
Premium
Liquid biopsy was comparable to tissue-based NGS in assessing EGFR mutations in the study, leading researchers to highlight the benefit of using both to expand patient access.
Korean AI Pathology Startup Lunit Nabs $26M Investment from Guardant Health; Plans Collaboration
Having closed a Series C funding round, the firm is completing clinical validation, and will collaborate with Guardant to develop new precision oncology products.
The firm announced the new test, Guardant360 Response, alongside its launch of its Guardant360 TissueNext tumor tissue genomic profiling product.